First-line treatment for clear cell renal cell carcinoma (CCRCC)

The recommended option is to participate in clinical trials.

For patients with a good/intermediate risk, the following treatments can be considered:

  1. Sunitinib, a drug that inhibits growth of blood vessels that cancers need to support their growth, thus preventing the growth of cancer cells.
  2. A treatment combination of bevacizumab and IFN-
  3. Pazopanib, a drug that blocks tumour growth. It also inhibits the growth of new blood vessels that cancers need to support their growth, thus preventing the growth of cancer cells.
  4. High-dose IL-2, a treatment that stimulates the body
  5. Active surveillance without drugs (Frequent follow-ups with the physician to check the status of the cancer)

For patients with poor risk, the following treatments can considered:

  1. Temsirolimus, a drug that inhibits tumour growth.
  2. Sunitinib, a drug that inhibits growth of blood vessels that cancers need to support their growth, thus preventing the growth of cancer cells.
  3. Pazopanib, a drug that blocks tumour growth. It also inhibits the growth of new blood vessels that cancers need to support their growth, thus preventing the growth of cancer cells.
  4. Best Supportive Care, medical care that focuses on relieving the symptoms caused by serious illnesses.